Oct. 22 at 2:30 PM
$SRRK Apitegromab combo with tirzepatide (Zepbound & Mounjaro) resulted in an improved preservation of lean muscle mass of 54.9% "GLP therapies have been an effective and important innovation for individuals living with obesity and cardiometabolic disorders; however, these treatments can result in substantial loss of lean muscle mass for patients, leading to unwanted health risks," remarked Akshay Vaishnaw, Scholar Rock's president of R&D.
The Phase II proof-of-concept study enrolled 102 patients with obesity or who were overweight with weight-related conditions. Patients receiving apitegromab with Zepbound lost 12.3% of their body weight after 24 weeks versus 13.4% for the arm that took Zepbound and a placebo.
However, the combo arm achieved 85.3% of total weight reduction coming from fat mass, with lean mass accounting for just 14.6% of the weight lost. The placebo group saw 69.5% of the total weight reduction coming from fat and 30.2% from lean mass.
